Maximilian Jenzer

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

Maximilian Jenzer, Peter Keß, Cathleen Nientiedt et al. · Cancer Immunology Immunotherapy · 2019 · 51 citations · Full text

Immunology, Immunoediting, Pathology +16

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy

Xin Chen, Christof Bernemann, Yuri Tolkach et al. · Urologic Oncology Seminars and Original Investigations · 2017 · 41 citations

Prognostic Biomarkers, Urology, Medicine +6

Community-driven development of a modified progression-free survival ratio for precision oncology

Andreas Möck, Christoph E. Heilig, Simon Kreutzfeldt et al. · ESMO Open · 2019 · 40 citations · Full text

Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers

Andreas Möck, Stefanie Zschäbitz, Romy Kirsten et al. · Cancer Immunology Immunotherapy · 2019 · 32 citations · Full text

Urology, Cancer Immunosurveillance, Checkpoint Inhibitors +9

Type-specific pneumococcal respiratory disease in the elderly and chronically III.

W M Valenti, Maximilian Jenzer, David W. Bentley · Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) · 1978 · 25 citations

Asthma, Vaccination, Epidemiology +15